Stay Ahead in Fast-Growing Economies.
Browse Reports Now
Somatropin Market Share, Trends & Market Forecast (2024-2032)
Somatropin is recombinant human growth hormone (rhGH) that is applied for a number of pathologies, which are associated with growth failure.
IMR Group
Description
Somatropin Market Synopsis:
Somatropin Market Size Was Valued at USD 4.25 Billion in 2023, and is Projected to Reach USD 7.94 Billion by 2032, Growing at a CAGR of 7.19% From 2024-2032.
Somatropin is recombinant human growth hormone (rhGH) that is applied for a number of pathologies, which are associated with growth failure. It fosters growth and it is used to treat hormonal deficiencies, Turner syndrome, and chronic kidney disease among other diseases. This agent is commonly given through injections in order to help develop tissues and bones.
Somatropin market has expanded all over the world due to its usage in treating patients with this hormone deficiency and other disorders affecting physical development. SOMATROPIN is one of the most frequently used recombinant hormones in clinical practice and is a synthetic growth hormone similar to that produced by the human pituitary gland. Although synthetic somatropin is used frequently than recombinant, Synthetic somatropin provides a cheaper solution to the problem in certain parts of the world.
Emerging diseases such as growth hormone deficiency, chronic kidney disease, idiopathic short stature will fuel the growth of the somatropin market. Besides, the emergence of new indications for somatropin incline Prader-Willi syndrome and Turner syndrome have broadened the supply side of this market. Publicity in refinement of recombinant somatropin and consistent endeavors to understand its therapeutic applications are the factors which are helping the market mature on the other hand. There exist advanced pharmaceutical formations and methods of drug administration which have been aimed at enhancing the quality of the results and administering the drugs easily.
As a result of widespread health consciousness across the world, crowding of healthcare products, especially for children and adolescents, whose physical stature is stunted, this product would be trendy in the marketplace. In addition, increased availability of new biosimilars is increasing affordability and cost- effectiveness of somatropin therapies and hence increasing their utilization. The demand for somatropin is also appraised in developed countries having good healthcare infrastructure, along with improved reimbursement policies in North America, European Union, and Asia-Pacific.
Somatropin Market Trend Analysis:
Growth in Biosimilars
The increase in biosimilars within the somatropin market allows for the formation of additional pricier but cost-effective forms of therapeutic recombinant human growth hormone compared to the initial innovation of first-generation r-hGH products on the market. Subsequently, biosimilars, which are products that are been formulated to be similar to an FDA-approved reference product, has received a fair deal of attention in different markets across the global especially the European and the North American markets. As healthcare systems strive to decrease their costs while upholding efficiency biosimilars help offset the cost of treatment.
It is predicted that high competition from biosimilars to somatropin will also establish a market competition thus lowering prices to avail appropriate treatments to patients. Therefore, there is improved access to cheaper medicines that help all healthcare providers treat individuals with growth hormone deficiency and all sorts of associated conditions. It is expected that this trend will enhance market development particularly the emerging markets where cost of health care is still a big issue of concern. As biosimilar development extends and regulatory clearances are accorded in the future, this part of the somatropin market should increase further.
Expanding in Emerging Markets
The somatropin market is benefited significantly from emerging markets due to better health care facility and better health care spending. Many developing nations in Asia-Pacific, Latin America, and some regions of the Middle East and Africa are getting better in terms of medical infrastructure and a fairly wealthy population than willing to spend on health. These regions will experience advancements in medical treatments’ availability so there will be increased demand of somatropin in the management of growth disorders.
There is growing emphasis on developing outreach for the utilization of health care services in such places. As the number of customers diagnosed with growth hormone deficiency and other conditions responsive to somatropin increases, there will be an increase in demand on the market. To a certain extent, the growth in the emerging markets could be attributed in the near-term to players that better manage the regulatory challenges, and those that are able to form strategic alliances with the local health care departments.
Somatropin Market Segment Analysis:
Somatropin Market is Segmented on the basis of Type, Application, Distribution Channel, End User, and Region.
By Product Type, Recombinant Somatropin segment is expected to dominate the market during the forecast period
Recombinant Somatropin of all the kinds of growth hormone that is administered to patients, recombinant somatropin is perhaps the most common. It is synthesized by the recombinant DNA technique and has the same molecular form of the biosynthetic growth hormone. This product type has stated growing particularly due to the disease severity attenuation by the product illustrated in the treatment of growth hormone deficiency and other related ailments.
Synthetic Somatropin Human somatropin is produced both in recombinant and synthetic formulations and the latter is cheaper but not as popular as the former. It is more commonly synthesized chemically than being made from recombinant DNA technology as may be expected. It is less effective than recombinant somatropin however, its application is limited because customers tend to buy recombinant somatropin as a purer alternative. The recombinant somatropin segment, in particular the segment related to GHN’s DNA expression system, is currently leading due to the higher efficiency and versatility of the product. The customer pressure for defining more affordable therapies, particularly throughout the developing countries, contributes to the expanded demand for synthetic somatropin. Nevertheless, the general inclination is in the direction of recombinant somatropin attributing to superior effective and more favorable patient choice.
By Application, Growth Hormone Deficiency segment expected to held the largest share
Growth Hormone Deficiency One of the most frequent uses of somatropin is in the treatment of any patient who has a deficiency in the body’s natural creation of growth hormone which results in slow growth. Turner Syndrome: Somatropin is urged to cure girls with Turner syndrome that is a chromosomal abnormality that affects height and other complications. Chronic Kidney Disease The children with chronic kidney disease are poorly grown, and somatropin is employed to facilitate the onset of some growth. Idiopathic Short Stature Somatropin is also used when no other cause of stunted growth is found and for idiopathic short stature to help the child grow taller.
Prader-Willi Syndrome Somatropin is prescribed to children with Prader-Willi syndrome which is a hereditary disorder and the main features of which are short height and learning difficulties. All of these applications are a major part of the somatropin market, though the largest application area is growth hormone deficiency. The markets for somatropin treatments in these regions will remain on the rise as awareness regarding the disease and its diagnosis grows.
Somatropin Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
The demand for somatropin is high in North America due to the better exposure of health care systems, high spending on health care, and better diagnostic structures. America alone is the largest consumer of somatropin mainly because of increased incidence of growth hormone deficiency and other related disorders. Furthermore, the augmentations in the demand of somatropin therapy across the globe make it possible for the region to afford the availability of both the branded and biosimilar products.
North America also holds a larger share in somatropin market because of availability of favourable regulatory environment adorned to the safety and effectiveness of these therapies. In addition, subsequent research and development work of large number of pharmaceutical firms located in this region has modified the somatropin product line as well as the modes of administration. The major factors restraining the growth of the somatropin market area Higher degree of patient awareness and a wider choice of treatments would allow North America to continue leading the somatropin market.
Active Key Players in the Somatropin Market
Anke Bio (China)
Biopartners (Switzerland)
Eli Lilly and Company (United States)
Genentech (United States)
Hugel, Inc. (South Korea)
LG Life Sciences (South Korea)
Merck & Co., Inc. (United States)
Novo Nordisk (Denmark)
Pfizer Inc. (United States)
Sandoz (Novartis) (Switzerland)
Stada Arzneimittel AG (Germany)
Teva Pharmaceutical Industries Ltd. (Israel)
Other Active Players.
Key Industry Developments in the Somatropin Market:
In April 2023, Novo Nordisk A/S, a global healthcare company, announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Sogroya (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg for the treatment of children aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone. With this new indication, Sogroya becomes the first and only once-weekly growth hormone (GH) treatment for both children and adults. The FDA approval of the new indication for children with GHD is based on data from the phase 3 REAL4 study.
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter’s Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Somatropin Market by Type
4.1 Somatropin Market Snapshot and Growth Engine
4.2 Somatropin Market Overview
4.3 Active Sonobuoy
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Active Sonobuoy: Geographic Segmentation Analysis
4.4 Passive Sonobuoy
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Passive Sonobuoy: Geographic Segmentation Analysis
4.5 Special Purpose Sonobuoy
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Special Purpose Sonobuoy: Geographic Segmentation Analysis
Chapter 5: Somatropin Market by Function
5.1 Somatropin Market Snapshot and Growth Engine
5.2 Somatropin Market Overview
5.3 Detection
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Detection: Geographic Segmentation Analysis
5.4 Location Identification
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Location Identification: Geographic Segmentation Analysis
5.5 Others
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Others: Geographic Segmentation Analysis
Chapter 6: Somatropin Market by Deployment
6.1 Somatropin Market Snapshot and Growth Engine
6.2 Somatropin Market Overview
6.3 Aircraft-based
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Aircraft-based: Geographic Segmentation Analysis
6.4 Ship-based
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Ship-based: Geographic Segmentation Analysis
Chapter 7: Somatropin Market by Application
7.1 Somatropin Market Snapshot and Growth Engine
7.2 Somatropin Market Overview
7.3 Defense
7.3.1 Introduction and Market Overview
7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.3.3 Key Market Trends, Growth Factors and Opportunities
7.3.4 Defense: Geographic Segmentation Analysis
7.4 Commercial
7.4.1 Introduction and Market Overview
7.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.4.3 Key Market Trends, Growth Factors and Opportunities
7.4.4 Commercial: Geographic Segmentation Analysis
Chapter 8: Somatropin Market by End User
8.1 Somatropin Market Snapshot and Growth Engine
8.2 Somatropin Market Overview
8.3 Naval Forces
8.3.1 Introduction and Market Overview
8.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
8.3.3 Key Market Trends, Growth Factors and Opportunities
8.3.4 Naval Forces: Geographic Segmentation Analysis
8.4 Marine Research Institutes
8.4.1 Introduction and Market Overview
8.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
8.4.3 Key Market Trends, Growth Factors and Opportunities
8.4.4 Marine Research Institutes: Geographic Segmentation Analysis
Chapter 9: Company Profiles and Competitive Analysis
9.1 Competitive Landscape
9.1.1 Competitive Benchmarking
9.1.2 Somatropin Market Share by Manufacturer (2023)
9.1.3 Industry BCG Matrix
9.1.4 Heat Map Analysis
9.1.5 Mergers and Acquisitions
9.2 GENENTECH – (UNITED STATES)
9.2.1 Company Overview
9.2.2 Key Executives
9.2.3 Company Snapshot
9.2.4 Role of the Company in the Market
9.2.5 Sustainability and Social Responsibility
9.2.6 Operating Business Segments
9.2.7 Product Portfolio
9.2.8 Business Performance
9.2.9 Key Strategic Moves and Recent Developments
9.2.10 SWOT Analysis
9.3 ELI LILLY AND COMPANY – (UNITED STATES)
9.4 NOVO NORDISK – (DENMARK)
9.5 MERCK & CO. INC. – (UNITED STATES)
9.6 SANDOZ (NOVARTIS) – (SWITZERLAND)
9.7 PFIZER INC. – (UNITED STATES)
9.8 HUGEL INC. – (SOUTH KOREA)
9.9 TEVA PHARMACEUTICAL INDUSTRIES LTD. – (ISRAEL)
9.10 BIOPARTNERS – (SWITZERLAND)
9.11 ANKE BIO – (CHINA)
9.12 STADA ARZNEIMITTEL AG – (GERMANY)
9.13 LG LIFE SCIENCES – (SOUTH KOREA)
9.14 OTHER ACTIVE PLAYERS
Chapter 10: Global Somatropin Market By Region
10.1 Overview
10.2. North America Somatropin Market
10.2.1 Key Market Trends, Growth Factors and Opportunities
10.2.2 Top Key Companies
10.2.3 Historic and Forecasted Market Size by Segments
10.2.4 Historic and Forecasted Market Size By Type
10.2.4.1 Active Sonobuoy
10.2.4.2 Passive Sonobuoy
10.2.4.3 Special Purpose Sonobuoy
10.2.5 Historic and Forecasted Market Size By Function
10.2.5.1 Detection
10.2.5.2 Location Identification
10.2.5.3 Others
10.2.6 Historic and Forecasted Market Size By Deployment
10.2.6.1 Aircraft-based
10.2.6.2 Ship-based
10.2.7 Historic and Forecasted Market Size By Application
10.2.7.1 Defense
10.2.7.2 Commercial
10.2.8 Historic and Forecasted Market Size By End User
10.2.8.1 Naval Forces
10.2.8.2 Marine Research Institutes
10.2.9 Historic and Forecast Market Size by Country
10.2.9.1 US
10.2.9.2 Canada
10.2.9.3 Mexico
10.3. Eastern Europe Somatropin Market
10.3.1 Key Market Trends, Growth Factors and Opportunities
10.3.2 Top Key Companies
10.3.3 Historic and Forecasted Market Size by Segments
10.3.4 Historic and Forecasted Market Size By Type
10.3.4.1 Active Sonobuoy
10.3.4.2 Passive Sonobuoy
10.3.4.3 Special Purpose Sonobuoy
10.3.5 Historic and Forecasted Market Size By Function
10.3.5.1 Detection
10.3.5.2 Location Identification
10.3.5.3 Others
10.3.6 Historic and Forecasted Market Size By Deployment
10.3.6.1 Aircraft-based
10.3.6.2 Ship-based
10.3.7 Historic and Forecasted Market Size By Application
10.3.7.1 Defense
10.3.7.2 Commercial
10.3.8 Historic and Forecasted Market Size By End User
10.3.8.1 Naval Forces
10.3.8.2 Marine Research Institutes
10.3.9 Historic and Forecast Market Size by Country
10.3.9.1 Russia
10.3.9.2 Bulgaria
10.3.9.3 The Czech Republic
10.3.9.4 Hungary
10.3.9.5 Poland
10.3.9.6 Romania
10.3.9.7 Rest of Eastern Europe
10.4. Western Europe Somatropin Market
10.4.1 Key Market Trends, Growth Factors and Opportunities
10.4.2 Top Key Companies
10.4.3 Historic and Forecasted Market Size by Segments
10.4.4 Historic and Forecasted Market Size By Type
10.4.4.1 Active Sonobuoy
10.4.4.2 Passive Sonobuoy
10.4.4.3 Special Purpose Sonobuoy
10.4.5 Historic and Forecasted Market Size By Function
10.4.5.1 Detection
10.4.5.2 Location Identification
10.4.5.3 Others
10.4.6 Historic and Forecasted Market Size By Deployment
10.4.6.1 Aircraft-based
10.4.6.2 Ship-based
10.4.7 Historic and Forecasted Market Size By Application
10.4.7.1 Defense
10.4.7.2 Commercial
10.4.8 Historic and Forecasted Market Size By End User
10.4.8.1 Naval Forces
10.4.8.2 Marine Research Institutes
10.4.9 Historic and Forecast Market Size by Country
10.4.9.1 Germany
10.4.9.2 UK
10.4.9.3 France
10.4.9.4 The Netherlands
10.4.9.5 Italy
10.4.9.6 Spain
10.4.9.7 Rest of Western Europe
10.5. Asia Pacific Somatropin Market
10.5.1 Key Market Trends, Growth Factors and Opportunities
10.5.2 Top Key Companies
10.5.3 Historic and Forecasted Market Size by Segments
10.5.4 Historic and Forecasted Market Size By Type
10.5.4.1 Active Sonobuoy
10.5.4.2 Passive Sonobuoy
10.5.4.3 Special Purpose Sonobuoy
10.5.5 Historic and Forecasted Market Size By Function
10.5.5.1 Detection
10.5.5.2 Location Identification
10.5.5.3 Others
10.5.6 Historic and Forecasted Market Size By Deployment
10.5.6.1 Aircraft-based
10.5.6.2 Ship-based
10.5.7 Historic and Forecasted Market Size By Application
10.5.7.1 Defense
10.5.7.2 Commercial
10.5.8 Historic and Forecasted Market Size By End User
10.5.8.1 Naval Forces
10.5.8.2 Marine Research Institutes
10.5.9 Historic and Forecast Market Size by Country
10.5.9.1 China
10.5.9.2 India
10.5.9.3 Japan
10.5.9.4 South Korea
10.5.9.5 Malaysia
10.5.9.6 Thailand
10.5.9.7 Vietnam
10.5.9.8 The Philippines
10.5.9.9 Australia
10.5.9.10 New Zealand
10.5.9.11 Rest of APAC
10.6. Middle East & Africa Somatropin Market
10.6.1 Key Market Trends, Growth Factors and Opportunities
10.6.2 Top Key Companies
10.6.3 Historic and Forecasted Market Size by Segments
10.6.4 Historic and Forecasted Market Size By Type
10.6.4.1 Active Sonobuoy
10.6.4.2 Passive Sonobuoy
10.6.4.3 Special Purpose Sonobuoy
10.6.5 Historic and Forecasted Market Size By Function
10.6.5.1 Detection
10.6.5.2 Location Identification
10.6.5.3 Others
10.6.6 Historic and Forecasted Market Size By Deployment
10.6.6.1 Aircraft-based
10.6.6.2 Ship-based
10.6.7 Historic and Forecasted Market Size By Application
10.6.7.1 Defense
10.6.7.2 Commercial
10.6.8 Historic and Forecasted Market Size By End User
10.6.8.1 Naval Forces
10.6.8.2 Marine Research Institutes
10.6.9 Historic and Forecast Market Size by Country
10.6.9.1 Turkiye
10.6.9.2 Bahrain
10.6.9.3 Kuwait
10.6.9.4 Saudi Arabia
10.6.9.5 Qatar
10.6.9.6 UAE
10.6.9.7 Israel
10.6.9.8 South Africa
10.7. South America Somatropin Market
10.7.1 Key Market Trends, Growth Factors and Opportunities
10.7.2 Top Key Companies
10.7.3 Historic and Forecasted Market Size by Segments
10.7.4 Historic and Forecasted Market Size By Type
10.7.4.1 Active Sonobuoy
10.7.4.2 Passive Sonobuoy
10.7.4.3 Special Purpose Sonobuoy
10.7.5 Historic and Forecasted Market Size By Function
10.7.5.1 Detection
10.7.5.2 Location Identification
10.7.5.3 Others
10.7.6 Historic and Forecasted Market Size By Deployment
10.7.6.1 Aircraft-based
10.7.6.2 Ship-based
10.7.7 Historic and Forecasted Market Size By Application
10.7.7.1 Defense
10.7.7.2 Commercial
10.7.8 Historic and Forecasted Market Size By End User
10.7.8.1 Naval Forces
10.7.8.2 Marine Research Institutes
10.7.9 Historic and Forecast Market Size by Country
10.7.9.1 Brazil
10.7.9.2 Argentina
10.7.9.3 Rest of SA
Chapter 11 Analyst Viewpoint and Conclusion
11.1 Recommendations and Concluding Analysis
11.2 Potential Market Strategies
Chapter 12 Research Methodology
12.1 Research Process
12.2 Primary Research
12.3 Secondary Research
Q1: What would be the forecast period in the Somatropin Market research report?
A1: The forecast period in the Somatropin Market research report is 2024-2032.
Q2: Who are the key players in the Somatropin Market?
A2: Genentech (United States), Eli Lilly and Company (United States), Novo Nordisk (Denmark), Merck & Co., Inc. (United States), Sandoz (Novartis) (Switzerland), Pfizer Inc. (United States), Hugel, Inc. (South Korea), and Other Active Players.
Q3: What are the segments of the Somatropin Market?
A3: The Somatropin Market is segmented into Product Type, Application, End User, Distribution Channel and region. By Product Type, the market is categorized into Recombinant Somatropin, Synthetic Somatropin. By Application, the market is categorized into Growth Hormone Deficiency, Turner Syndrome, Chronic Kidney Disease, Idiopathic Short Stature, Prader-Willi Syndrome, Others. By End-User, the market is categorized into Hospitals, Clinics, Homecare Settings. By Distribution Channel, the market is categorized into Direct Tender, Retail Pharmacies, Online Pharmacies. By region, it is analyzed across North America (U.S., Canada, Mexico), Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe), Western Europe (Germany, UK, France, The Netherlands, Italy, Russia, Spain, Rest of Western Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC), Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil, Argentina, Rest of SA).
Q4: What is the Somatropin Market?
A4: Somatropin is recombinant human growth hormone (rhGH) that is applied for a number of pathologies, which are associated with growth failure. It fosters growth and it is used to treat hormonal deficiencies, Turner syndrome, and chronic kidney disease among other diseases. This agent is commonly given through injections in order to help develop tissues and bones.
Q5: How big is the Somatropin Market?
A5: Somatropin Market Size Was Valued at USD 4.25 Billion in 2023, and is Projected to Reach USD 7.94 Billion by 2032, Growing at a CAGR of 7.19% From 2024-2032.
How to Buy a Report from eminsights.jp
On the product page, choose the license you want: Single-User License, Multi-User License or Enterprise License.
If you required report in your native language, then you can click on Translated Report button and fill out the form with report name and language you want, then our team will contact you as soon as possible.
Click the Buy Now button.
You will be redirected to the checkout page. Enter your company details and payment information.
Click Place Order to complete the purchase.
Confirmation: You’ll receive an order confirmation and our team will contact you shortly with your ordered report.
If you have any questions, fill out the contact form below or email us at bizdev@eminsights.net.
Thank you for choosing eminsights.jp!
